These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 37974030

  • 1. Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD.
    Knol MGE, Bais T, Geertsema P, Connelly MA, Bakker SJL, Gansevoort RT, van Gastel MDA, DIPAK Consortium .
    Nephrol Dial Transplant; 2024 Apr 26; 39(5):838-847. PubMed ID: 37974030
    [Abstract] [Full Text] [Related]

  • 2. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E, DIPAK Consortium.
    BMC Nephrol; 2018 Dec 19; 19(1):368. PubMed ID: 30567514
    [Abstract] [Full Text] [Related]

  • 3. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT, on behalf of the DIPAK-1 study investigators.
    Am J Nephrol; 2019 Dec 19; 50(5):375-385. PubMed ID: 31600749
    [Abstract] [Full Text] [Related]

  • 4. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
    Griffin BR, You Z, Noureddine L, Gitomer B, Perrenoud L, Wang W, Chonchol M, Jalal D, the HALT Investigators.
    Am J Nephrol; 2020 Dec 19; 51(6):473-479. PubMed ID: 32541154
    [Abstract] [Full Text] [Related]

  • 5. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M.
    Clin J Am Soc Nephrol; 2017 Sep 07; 12(9):1461-1469. PubMed ID: 28705885
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
    Heida JE, Gansevoort RT, Messchendorp AL, Meijer E, Casteleijn NF, Boertien WE, Zittema D, DIPAK Consortium.
    Clin J Am Soc Nephrol; 2021 Feb 08; 16(2):204-212. PubMed ID: 33504546
    [Abstract] [Full Text] [Related]

  • 8. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
    Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).
    Kidney Int; 2018 Mar 08; 93(3):691-699. PubMed ID: 29290310
    [Abstract] [Full Text] [Related]

  • 9. Urinary biomarkers at early ADPKD disease stage.
    Petzold K, Poster D, Krauer F, Spanaus K, Andreisek G, Nguyen-Kim TD, Pavik I, Ho TA, Serra AL, Rotar L.
    PLoS One; 2015 Mar 08; 10(4):e0123555. PubMed ID: 25875363
    [Abstract] [Full Text] [Related]

  • 10. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
    Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, DIPAK Consortium.
    Am J Kidney Dis; 2014 Mar 08; 63(3):446-55. PubMed ID: 24342522
    [Abstract] [Full Text] [Related]

  • 11. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.
    Girardat-Rotar L, Puhan MA, Braun J, Serra AL.
    J Nephrol; 2018 Feb 08; 31(1):87-94. PubMed ID: 28386880
    [Abstract] [Full Text] [Related]

  • 12. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, Sekine A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Takaichi K.
    J Nephrol; 2018 Dec 08; 31(6):961-966. PubMed ID: 30357715
    [Abstract] [Full Text] [Related]

  • 13. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC, Kim J, Cho A, Kim DH, Lee YK, Ryu H, Kim H, Oh KH, Oh YK, Hwang YH, Lee KB, Kim SW, Kim YH, Lee J, Ahn C, KNOW-CKD Investigators Group.
    J Korean Med Sci; 2020 Jun 08; 35(22):e165. PubMed ID: 32508065
    [Abstract] [Full Text] [Related]

  • 14. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B, Treesinchai W, Wibulpolprasert P, Boongird S, Klytrayong P.
    BMC Nephrol; 2021 May 15; 22(1):178. PubMed ID: 33992075
    [Abstract] [Full Text] [Related]

  • 15. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K, Mochizuki T, Shimada Y, Nishio S, Kataoka H, Mitobe M, Tsuchiya K, Hanaoka K, Ubara Y, Suwabe T, Sekine A, Nutahara K, Tsuruya K, Ishimura E, Nakatani S, Sofue T, Tanaka S, Narita I, Maruyama S, Horie S, Muto S.
    Clin Exp Nephrol; 2021 Sep 15; 25(9):970-980. PubMed ID: 33928479
    [Abstract] [Full Text] [Related]

  • 16. Increased Body Fat and Organic Acid Anions Production Are Associated with Larger Kidney Size in ADPKD.
    Dos Santos Dutra A, Rodrigues FG, da Rocha DR, Vendramini LC, de Matos ACC, Heilberg IP.
    Medicina (Kaunas); 2022 Jan 19; 58(2):. PubMed ID: 35208476
    [Abstract] [Full Text] [Related]

  • 17. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ, CRISP Investigators.
    Kidney Int; 2017 Nov 19; 92(5):1206-1216. PubMed ID: 28532709
    [Abstract] [Full Text] [Related]

  • 18. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E, Yamamoto K, Kaname S, Okegawa T, Tanbo M, Yamaguchi T, Shigemori K, Miyazaki I, Yokoyama K, Nutahara K.
    Clin Exp Nephrol; 2019 Jan 19; 23(1):100-111. PubMed ID: 30097754
    [Abstract] [Full Text] [Related]

  • 19. Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease.
    Blijdorp CJ, Severs D, Musterd-Bhaggoe UM, Gansevoort RT, Zietse R, Hoorn EJ, DIPAK Consortium.
    Nephrol Dial Transplant; 2021 Dec 02; 36(12):2248-2255. PubMed ID: 33377160
    [Abstract] [Full Text] [Related]

  • 20. Kidney Energetics and Cyst Burden in Autosomal Dominant Polycystic Kidney Disease: A Pilot Study.
    Bjornstad P, Richard G, Choi YJ, Nowak KL, Steele C, Chonchol MB, Nadeau KJ, Vigers T, Pyle L, Tommerdahl K, van Raalte DH, Hilkin A, Driscoll L, Birznieks C, Hopp K, Wang W, Edelstein C, Nelson RG, Gregory AV, Kline TL, Blondin D, Gitomer B.
    Am J Kidney Dis; 2024 Sep 02; 84(3):286-297.e1. PubMed ID: 38621633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.